Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

NCT01679990 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Intermittent Claudication
Peripheral Artery Disease

Interventions

BIOLOGICAL: PLX-PAD Low dose
BIOLOGICAL: PLX-PAD high doses
BIOLOGICAL: Double Placebo
BIOLOGICAL: high dose +Placebo

Sponsor

Pluristem Ltd.